Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Algert Global LLC lessened its holdings in shares of Glaukos Corporation (NYSE: GKOS) by 43.0% in th

Glaukos (NYSE:GKOS) has outperformed the market over the past 5 years by 15.09% on an annualized bas

Deutsche Bank AG acquired a new stake in Glaukos Corporation (NYSE: GKOS) during the undefined quart

Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a b

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target

Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline s

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Small-cap stocks are surging, but how you own them matters more than most investors realize.

First Trust Advisors LP increased its holdings in Glaukos Corporation (NYSE: GKOS) by 2,085.8% in th

UBS analyst Patrick Wood maintains Glaukos (NYSE:GKOS) with a Neutral and raises the price target

HC Wainwright & Co. analyst Yi Chen maintains Glaukos (NYSE:GKOS) with a Buy and raises the p

Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Buy and raises the price ta

Piper Sandler analyst Adam Maeder reiterates Glaukos (NYSE:GKOS) with a Overweight and raises the

Stifel analyst Tom Stephan maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target f

GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales out

Truist Securities analyst Richard Newitter maintains Glaukos (NYSE:GKOS) with a Buy and raises th

Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:GKOS) with a Overweight and raises th

Needham analyst David Saxon maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target

BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target

Glaukos NYSE: GKOS reported record second-quarter 2026 consolidated net sales of $185.6 million, up

Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the qu

Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (GKOS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate

Glaukos (NYSE:GKOS) raises FY2026 sales outlook from $620.000 million-$635.000 million to $680.000 m

Glaukos (NYSE:GKOS) reported quarterly losses of $(0.14) per share which beat the analyst consensus

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Glaukos Corporation remains rated "Hold" as shares approach technical resistance near $160 ahead of

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Bank of New York Mellon Corp reduced its stake in shares of Glaukos Corporation (NYSE: GKOS) by 3.6%

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Stifel analyst Tom Stephan maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target f

Truist Securities analyst Richard Newitter maintains Glaukos (NYSE:GKOS) with a Buy and raises th

Alex R. Thurman generated ~$1.6 million in gross proceeds by selling 10,000 shares at $155 per share

Abbott Laboratories offers a highly diversified healthcare portfolio with strong profitability acros

GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expe

Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Buy and raises the price ta

HC Wainwright & Co. analyst Yi Chen initiates coverage on Glaukos (NYSE:GKOS) with a Buy rati

Piper Sandler analyst Adam Maeder reiterates Glaukos (NYSE:GKOS) with a Overweight and maintains

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused

Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J

Needham analyst David Saxon maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target

Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Buy and raises the price ta

Wall Street analysts change outlook on top stocks. For full list of changes including upgrades/downg

BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target

JP Morgan analyst Allen Gong maintains Glaukos (NYSE:GKOS) with a Overweight and raises the price

Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Buy and raises the price ta